drug · small molecule

ORLADEYO

updated 3mo ago

by $BCRX BIOCRYST PHARMACEUTICALS INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.

targets

Plasma kallikrein

all catalysts(0)

nothing on the calendar yet

News(1)

‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.
fiercebiotech · 3d ago

brand

ORLADEYO

trade names

Orladeyo

generic

BEROTRALSTAT DIHYDROCHLORIDE

MOA

12.1 Mechanism of Action Berotralstat is a plasma kallikrein inhibitor that binds to plasma kallikrein and inhibits its proteolytic activity. Plasma kallikrein is a protease that cleaves high-molecular-weight kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin, a potent vasodilator that increases vascular permeability resulting in swelling and pain associated with HAE. In patients with HAE due to C1-inhibitor (C1-INH) deficiency or dysfunction, normal regulation of plasma kallikrein activity is not present, which leads to uncontrolled increases in plasma kallikrein activity and results in angioedema attacks. Berotralstat decreases plasma kallikrein activity to control excess bradykinin generation in patients with HAE.

indication

1 INDICATIONS AND USAGE ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years of age and older. ORLADEYO is a plasma kallikrein inhibitor indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 2 years and older. ( 1 ) Limitations of Use : ORLADEYO should not be used for treatment of acute HAE attacks. ( 1 ) Limitations of Use : The safety and effectiveness of ORLADEYO for the treatment of acute HAE attacks have not been established. ORLADEYO should not be used for treatment of acute HAE attacks. Additional doses or doses of ORLADEYO higher than the prescribed once-daily dose are not recommended due to the potential for QTc interval prolongation [see Warnings and Precautions (5.1) ] .

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 46m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · small molecule

save

ORLADEYO

updated 3mo ago

by $BCRX BIOCRYST PHARMACEUTICALS INC🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 3

Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for 4 indications.

targets

Plasma kallikrein

all catalysts(0)

nothing on the calendar yet

News(1)

‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discovery
BioCryst CEO Charlie Gayer told Fierce the company is “not getting away from science and R&D” despite shutting down its internal discovery efforts.
fiercebiotech · 3d ago

brand

ORLADEYO

trade names

Orladeyo

generic

BEROTRALSTAT DIHYDROCHLORIDE

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 46m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

ORLADEYO

🐶 often sniffed alongside

targets

all catalysts(0)

News(1)

Report a data issue

comments(0)

ORLADEYO

🐶 often sniffed alongside

targets

all catalysts(0)

News(1)

Report a data issue

comments(0)